Uni-Bio Science Group Ltd 2022 SR
The report highlights Uni-Bio Science Group's 2022 ESG performance, focusing on its biopharmaceutical operations in Beijing, Shenzhen, and Hong Kong. Key achievements include the successful market launch of four products and winning national drug procurement bids, expanding hospital market share. The company invested HK$54 million in R&D and achieved a 5.4% reduction in greenhouse gas emissions compared to 2021. It also completed intelligent transformations of distribution rooms to enhance fire and electrical safety. The report emphasizes a 'People First' approach, maintaining a 100% employee training rate and zero workplace fatalities.
Company: Uni-Bio Science Group Ltd
Sector: Health Care
Country: Hong Kong
Year: 2022
Type: SR
Pages: 37
Uni-Bio Science Group Ltd
ESG Report
The report highlights Uni-Bio Science Group's 2022 ESG performance, focusing on its biopharmaceutical operations in Beijing, Shenzhen, and Hong Kong. Key achievements include the successful market launch of four products and winning national drug procurement bids, expanding hospital market share. The company invested HK$54 million in R&D and achieved a 5.4% reduction in greenhouse gas emissions compared to 2021. It also completed intelligent transformations of distribution rooms to enhance fire and electrical safety. The report emphasizes a 'People First' approach, maintaining a 100% employee training rate and zero workplace fatalities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees